Perhaps 40% of persons with genetically confirmed long-QT syndrome (LQTS) do not show the telltale electrocardiographic (ECG) feature, a prolonged heart-rate-corrected QT (QTc) interval, when their 12 ...
MONTREAL, Aug. 25, 2023 /PRNewswire/ - Thryv Therapeutics Inc. today announced positive results of the WAVE 1 Proof of Concept clinical study evaluating LQT-1213 for the reduction of QTcF in ...
As more consumer-facing devices add features to measure the heart’s electrical activity, companies are looking for new ways to turn this data into valuable health information. AliveCor, a startup that ...
The QT interval is the time from the beginning of the QRS complex (ventricular depolarization) to the end of the T wave (ventricular repolarization). The normal QT interval is controversial and ...
SAN FRANCISCO -- Cardiac repolarization dynamics seemed to cycle in sync with the menstrual cycle of some people with congenital and drug-induced long QT syndrome (LQTS), a small prospective study ...
ROCHESTER, MN — A significant number of patients given implantable cardioverter defibrillators (ICDs) for long-QT syndrome (LQTS) receive them for reasons outside of current guidelines, and many ...
LQT-1213 is a first-in-class serum glucocorticoid regulated kinase 1 inhibitor. The Food and Drug Administration (FDA) has granted Orphan Drug designation to LQT-1213, a first-in-class serum ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results